Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

TSX:ERD
TSX:ERDMetals and Mining

Discovering Undiscovered Gems in Canada This May 2026

As the Canadian market navigates the complexities of global geopolitical tensions and recent improvements in the U.S. labor market, investors are increasingly turning their attention to small-cap stocks that may have been overlooked amid broader economic discussions. In this dynamic environment, identifying promising small-cap companies involves assessing their potential for growth and resilience in light of shifting economic fundamentals and evolving market sentiment.
NYSE:FIGS
NYSE:FIGSLuxury

Why FIGS (FIGS) Is Down 16.8% After Raising 2026 Revenue Guidance on Strong Q1 Results

In the first quarter of 2026, FIGS, Inc. reported net revenue of US$159.9 million, up from US$124.9 million a year earlier, and moved from a small net loss to net income of US$6.29 million, with basic earnings per share of US$0.04. The company’s strong quarter was underpinned by 28% year-over-year net revenue growth, passing three million active customers and prompting management to raise full-year 2026 revenue guidance to 14%–16% growth, even as this implied slower growth than the first...
NasdaqGS:PRAX
NasdaqGS:PRAXBiotechs

Does FDA Review Of Ulixacaltamide And Relutrigine Reshape The Bull Case For Praxis (PRAX)?

In early May 2026, Praxis Precision Medicines reported a first-quarter net loss of US$92.56 million, while also securing FDA acceptance of new drug applications for ulixacaltamide in essential tremor and relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies. Alongside these filings, Praxis highlighted positive early-stage data for elsunersen showing a very large placebo-adjusted seizure reduction in SCN2A-DEE, underscoring growing clinical momentum across its central...